Abstract: Objective To explore the value of blood coagulation function test in patients with pregnancy-induced hypertension syndrome and gestational diabetes mellitus. Methods From January 2016 to January 2018, 338 cases of gestational diabetes admitted to our hospital were used as diabetes group, 188 cases of hypertensive syndrome of pregnancy were used as hypertension group, and 360 cases of normal pregnant women admitted to hospital at the same time were selected as normal group. All patients and their families had informed consent to the study. The changes and adverse outcomes of plasma prothrombin time (PT), fibrinogen (FIB), activated partial thromboplastin time (APTT) and D-dimer (DD) in different pregnancy stages were observed and analyzed. Results In the first trimester, PT, APTT, FIB, and D-D were not significantly different between the three groups (F=0.804, 0.401, 1.115, 0.813, P=0.528, 0.754, 0.359, 0.809). In the second trimester, the PT and APTT in the diabetic group and the hypertension group were significantly lower than those in the normal group. The FIB and D-D in the diabetic group and the hypertension group were significantly higher than those in the normal group. In the third trimester, the PT and APTT in the diabetic group and the hypertension group were significantly lower than those in the normal group; the FIB and D-D in the diabetic group and the hypertension group were significantly higher than those in the normal group. The incidence of adverse outcomes was statistically significant among the three groups (χ²=15.449, P=0.001). The incidence of adverse outcomes was significantly higher in the diabetic group and the hypertension group than in the normal group. Conclusion GDM patients and hypertensive patients with gestational age are in a relatively hypercoagulable state during the middle and late pregnancy, and it is of great significance to dynamically detect various coagulation indexes.